ZA96100B - Substituted oxazolidine calpain and/or cathepsin b inhibitors - Google Patents

Substituted oxazolidine calpain and/or cathepsin b inhibitors

Info

Publication number
ZA96100B
ZA96100B ZA96100A ZA96100A ZA96100B ZA 96100 B ZA96100 B ZA 96100B ZA 96100 A ZA96100 A ZA 96100A ZA 96100 A ZA96100 A ZA 96100A ZA 96100 B ZA96100 B ZA 96100B
Authority
ZA
South Africa
Prior art keywords
calpain
cathepsin
inhibitors
substituted oxazolidine
oxazolidine
Prior art date
Application number
ZA96100A
Other languages
English (en)
Inventor
Norton Paul Peet
Shujaath Mehdi
Matthew David Linnik
Michael Richard Angelastro
Hwa-Ok Kim
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of ZA96100B publication Critical patent/ZA96100B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA96100A 1995-01-11 1996-01-08 Substituted oxazolidine calpain and/or cathepsin b inhibitors ZA96100B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37119295A 1995-01-11 1995-01-11

Publications (1)

Publication Number Publication Date
ZA96100B true ZA96100B (en) 1996-07-24

Family

ID=23462894

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA96100A ZA96100B (en) 1995-01-11 1996-01-08 Substituted oxazolidine calpain and/or cathepsin b inhibitors

Country Status (23)

Country Link
US (1) US5691368A (fr)
EP (1) EP0802909B1 (fr)
JP (1) JP4157601B2 (fr)
KR (1) KR100393701B1 (fr)
CN (1) CN1088456C (fr)
AR (1) AR001787A1 (fr)
AT (1) ATE206413T1 (fr)
AU (1) AU692044B2 (fr)
CA (1) CA2210258C (fr)
DE (1) DE69523072T2 (fr)
DK (1) DK0802909T3 (fr)
ES (1) ES2165441T3 (fr)
FI (1) FI972935A0 (fr)
HU (1) HUT77649A (fr)
IL (1) IL116724A (fr)
MX (1) MX9705235A (fr)
NO (1) NO309267B1 (fr)
NZ (1) NZ298999A (fr)
PT (1) PT802909E (fr)
SI (1) SI0802909T1 (fr)
TW (1) TW454001B (fr)
WO (1) WO1996021655A2 (fr)
ZA (1) ZA96100B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270882B (it) * 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
US5925633A (en) * 1996-03-06 1999-07-20 Synphar Laboraties, Inc. 3-Substituted-4-oxa-1-azabicyclo 3,2,0!heptan-7-one as cysteine protease inhibitors
AU6134498A (en) * 1997-03-07 1998-09-22 Hoechst Marion Roussel, Inc. Method of treating trauma associated with brain, spinal cord or peripheral nerveinjury using carbobenzyloxy n-protected di- and tripeptide phenylalaninals
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
CA2350133A1 (fr) * 1998-11-12 2000-05-18 Research Corporation Technologies, Inc. Traitement de tissus ischemiquement degrades
WO2000051998A1 (fr) * 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
JP2002539190A (ja) 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物および組成物
TW200404789A (en) 1999-03-15 2004-04-01 Axys Pharm Inc Novel compounds and compositions as protease inhibitors
EP1516877A1 (fr) * 1999-03-15 2005-03-23 Axys Pharmaceuticals, Inc. Derivés d'amine comme inhibiteurs de protease
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2800737B1 (fr) * 1999-11-05 2006-06-30 Sod Conseils Rech Applic Nouveaux composes heterocycliques et leur application a titre de medicaments
PT1233962E (pt) * 1999-11-05 2006-07-31 Sod Conseils Rech Applic Compostos heterociclicos e a sua utilizacao como medicamentos
EP1315971A2 (fr) * 2000-07-31 2003-06-04 The Regents of The University of California Modele pour la maladie d'alzheimer et autres maladies neurodegenerative
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
BR0212535A (pt) 2001-09-14 2004-10-19 Aventis Pharma Inc Compostos e composições como inibidores de catepsina
RU2004117877A (ru) 2001-11-14 2006-01-10 Авентис Фармасьютикалз Инк. (Us) Олигопептиды и композиции, содержащие их, в качестве ингибиторов катепсина s
WO2004084830A2 (fr) * 2003-03-21 2004-10-07 Buck Institute Méthode de traitement de la maladie d'alzheimer
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (fr) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Utilisation d'un inhibiteur de la cathepsine-s ou -b afin de traiter ou de prevenir les maladies pulmonaires obstructives chroniques
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
FR2863268B1 (fr) * 2003-12-09 2006-02-24 Sod Conseils Rech Applic Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
EP2300000A1 (fr) * 2008-07-03 2011-03-30 University of Massachusetts Procédés et compositions pour réduire une inflammation et traiter des troubles inflammatoires
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2542549B1 (fr) 2010-03-03 2016-05-11 Probiodrug AG Inhibiteurs de glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2024018245A1 (fr) 2022-07-22 2024-01-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de calpaïne pour le traitement de la maladie rénale diabétique
WO2024153744A1 (fr) 2023-01-20 2024-07-25 Institut National de la Santé et de la Recherche Médicale Activateurs d'autophagie pour le traitement de la rhabdomyolyse
WO2025153685A1 (fr) * 2024-01-18 2025-07-24 Firmenich Sa Pro-parfums de 3-acyl-oxazolidin-5-one

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867364A (en) * 1968-11-21 1975-02-18 Microbial Chem Res Found Process for the synthesis of leupeptins and their analogues
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4277395A (en) * 1980-06-16 1981-07-07 Richardson-Merrell Inc. Novel enzyme inhibitors
JPS5754157A (en) * 1980-09-19 1982-03-31 Nippon Kayaku Co Ltd L-argininal derivative and its preparation
US4535167A (en) * 1981-12-14 1985-08-13 Merck & Co. Inc. Chiral, N-protected, N-substituted α-amino acids
WO1984000365A1 (fr) * 1982-07-19 1984-02-02 Nat Res Dev Peptides synthetiques et leur preparation
US5091575A (en) * 1985-01-23 1992-02-25 Abbott Laboratories Peptidylaminodiols
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5214129A (en) * 1985-01-23 1993-05-25 Abbott Laboratories Peptidylaminodiols
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
JPH079705B2 (ja) * 1986-05-28 1995-02-01 オリンパス光学工業株式会社 光カ−ド用デ−タ記録再生装置
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US5032577A (en) * 1986-12-31 1991-07-16 Abbott Laboratories Peptidylaminodiols
NZ223148A (en) * 1987-01-16 1989-10-27 Merrell Dow Pharma Peptide derivatives having peptidase inhibition activity
US4820691A (en) * 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
EP0313847A3 (fr) * 1987-10-01 1989-11-29 G.D. Searle & Co. Alpha-succinamidoacyl aminodiols non peptidiques comme agents anti-hypertensifs
EP0329295A1 (fr) * 1988-02-01 1989-08-23 The Upjohn Company Peptides inhibant la rénine avec des groupes terminaux polaires
AU3964489A (en) * 1988-07-08 1990-02-05 Smithkline Beckman Corporation Retroviral protease binding peptides
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4990525A (en) * 1988-12-22 1991-02-05 Rohm And Haas Company Synergistic microbicidal combinations containing 3-isothiazolone and commerical biocides
US5510531A (en) * 1989-04-10 1996-04-23 Suntory Limited Proteinase inhibitor
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
CA2032259A1 (fr) * 1989-12-18 1991-06-19 Wayne J. Thompson Inhibiteurs de la protease du vih utiles dans le traitement du sida
EP0665215A1 (fr) * 1990-06-01 1995-08-02 The Du Pont Merck Pharmaceutical Company 1,4-diamino-2,3-dihydroxybutanes
DE4037437A1 (de) * 1990-11-24 1992-05-27 Hoechst Ag Aminodiol-derivate
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
AU667463B2 (en) * 1990-12-28 1996-03-28 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
CA2071621C (fr) * 1991-06-19 1996-08-06 Ahihiko Hosoda Derives d'aldehyde
JP3190431B2 (ja) * 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
AU655831B2 (en) * 1991-08-22 1995-01-12 Merrell Pharmaceuticals Inc. Novel orally-active elastase inhibitors
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
EP0603769B1 (fr) * 1992-12-25 1998-09-16 Mitsubishi Chemical Corporation Dérivés d'alpha-aminocétones
JP2848232B2 (ja) * 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
HU221629B1 (hu) * 1993-10-01 2002-12-28 Merrell Pharmaceuticals Inc. Béta-amiloid fehérje képződést gátló peptidek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
AU4473196A (en) 1996-07-31
MX9705235A (es) 1997-10-31
NZ298999A (en) 1999-01-28
PT802909E (pt) 2002-03-28
AR001787A1 (es) 1997-12-10
HUT77649A (hu) 1998-07-28
FI972935L (fi) 1997-07-10
NO309267B1 (no) 2001-01-08
DK0802909T3 (da) 2002-01-28
NO973216L (no) 1997-09-09
IL116724A0 (en) 1996-05-14
EP0802909A2 (fr) 1997-10-29
KR100393701B1 (ko) 2003-11-28
CN1088456C (zh) 2002-07-31
FI972935A7 (fi) 1997-07-10
ATE206413T1 (de) 2001-10-15
WO1996021655A2 (fr) 1996-07-18
SI0802909T1 (en) 2002-02-28
WO1996021655A3 (fr) 1996-09-06
DE69523072D1 (en) 2001-11-08
CN1173174A (zh) 1998-02-11
JPH10512257A (ja) 1998-11-24
CA2210258A1 (fr) 1996-07-18
DE69523072T2 (de) 2002-06-20
TW454001B (en) 2001-09-11
NO973216D0 (no) 1997-07-10
FI972935A0 (fi) 1997-07-10
US5691368A (en) 1997-11-25
ES2165441T3 (es) 2002-03-16
JP4157601B2 (ja) 2008-10-01
AU692044B2 (en) 1998-05-28
EP0802909B1 (fr) 2001-10-04
IL116724A (en) 2000-08-31
CA2210258C (fr) 2002-10-01

Similar Documents

Publication Publication Date Title
IL116724A0 (en) Substituted oxazolidine calpain and/or cathepsin B inhibitors
PL326508A1 (en) Protease inhibitors
IL130124A0 (en) Ketobenzamides as calpain inhibitors
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
MXPA99002203A (es) Nuevos derivados de acetamida e inhibidores de proteasa.
PL327569A1 (en) Promedications of thrombosin inhibitors
HU9601508D0 (en) Dp-iv-serine protease inhibitors
HU9202842D0 (en) Climotripsine-type proteases and inhibitors
IL117638A0 (en) Reversible protease inhibitors
EP0744948A4 (fr) Inhibiteurs de protease
PL328877A1 (en) Method of inhibiting cathepsin k
EP0831920A4 (fr) Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine
GB9624731D0 (en) Complement inhibitor
HUP9802764A3 (en) Guanidino protease inhibitors
IL123268A0 (en) PEP inhibitor
ZA946325B (en) Retroviral protease inhibitors and combinations thereof.
IL114201A0 (en) Inhibitor
AU5014496A (en) Diphenylmethyl-azetidinone compounds and elastase inhibitor
IL112244A0 (en) Novel inhibitor
GB9510563D0 (en) Well inhibition
BR9303279A (pt) Inibição de nitrosamina e nitreto
GB9520761D0 (en) Protease inhibitors
ZA963223B (en) Drill steels
GB9423477D0 (en) Proteinase inhibitors
PL103743U1 (en) Wrist protector